Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CNS Pharmaceuticals, Inc. entered into Securities Purchase Agreement with an institutional investor valued at approximately $6.0 million.
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional investor
- Value
- approximately $6.0 million
Exact text from the filing
On November 30 2022, CNS Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor for the sale by the Company of (i) 147,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,742,764 shares of Common Stock and (iii) warrants to purchase up to an aggregate of 1,889,764 shares of Common Stock (the “Common Warrants” and, collectively with the Pre-Funded Warrants, the “Warrants”), in a public offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CNS Pharmaceuticals, Inc. entered into Placement Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2022-11-30).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC
- Effective
- 2022-11-30
Exact text from the filing
On November 30, 2022, the Company entered into a placement agency agreement with H.C. Wainwright & Co., LLC (“Wainwright”) and Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline” and collectively with Wainright, the “Placement Agents”) (the “Placement Agreement”), pursuant to which the Company has agreed to pay the Placement Agents an aggregate fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the transaction.
View on SEC.gov